Merz Pharmaceuticals Announces Approval Of Post-stroke Upper Limb Spasticity Indication For Xeomin(R) In The EU
Links shared publicly online about this topic.
- 1,591total visits
Merz Pharmaceuticals Announces Approval Of Post-stroke Upper Limb Spasticity Indication For Xeomin(R) In The EU
Merz Pharmaceuticals announced Xeomin®, the first botulinum toxin type A free from complexing proteins has been granted an extension of indication for post-stroke spasticity of the upper limb
View full resource at medicalnewstoday.com
Tags: Poison, Botulism, Protein, Pharma
Most Recently Shared on November 19, 2009 at 3:13 pm By:
Merz Pharmaceuticals Announces Approval Of Post-stroke Upper Limb Spasticity Indication For Xeomin(R) In The EU.. http://bit.ly/21t78m
Advertisement
